Blass, Eryn
Ott, Patrick A.
Article History
Accepted: 30 November 2020
First Online: 20 January 2021
Competing interests
: P.A.O. has received research funding from and has been an adviser of Amgen, Armo BioSciences, Array, AstraZeneca/MedImmune, Bristol-Myers Squibb, Celldex, CytomX, Merck, Neon Therapeutics, Novartis, Pfizer and Roche/Genentech. E.B. declares no competing interests.
Free to read: This content has been made available to all.